The company received the award in the category “Pharmaceuticals and Microbiology” for the development of Cegardex, the first Russian human papillomavirus (HPV) vaccine, and for launching its full-cycle production.

The award ceremony took place on November 25 in Moscow at the Civic Chamber of the Russian Federation.

“The launch of a fully Russian-made HPV vaccine will significantly strengthen cervical cancer prevention in our country and make a real contribution to addressing this complex medical, social, and demographic challenge,” said Evgeny Barinov, CEO of Nanolek.

Cegardex is a development of Russian scientists. Full-cycle production — from antigen manufacturing to the release of the finished dosage form — is organized at the Nanolek Biomedical Complex in the Kirov region. The first production unit was opened on October 29, 2025. The first commercial batches are expected to enter civilian circulation in the second half of 2026.

The vaccine protects against four of the most common and dangerous HPV types — 6, 11, 16, and 18 — associated with cervical cancer, anal cancer, and cutaneous lesions such as papillomas. In March 2025, Cegardex received a marketing authorization for adult use. Clinical studies involving children have been completed: 402 volunteers aged 9 to 17 took part. Indication expansion to include this age group is expected in February 2026.

The Priority Award has been presented annually since 2015 for achievements in the development, implementation, and promotion of advanced Russian technologies across all sectors of industry and information technology. The award is held with the support of the Chamber of Commerce and Industry of the Russian Federation, the Russian Engineering Union, and other public organizations.